To evaluate the diagnostic value of a high preoperative PSA level for the detection of incidental prostate cancer (iPCa) in LUTS patients with very large prostates (> 100 cc).
We conducted a retrospective analysis of 1125 men treated for LUTS with holmium laser enucleation of the prostate (HoLEP). Patients were stratified according to a preoperative PSA level higher (high PSA; n = 365) or lower than 10 ng/ml (low PSA; n = 760). Preoperative and histopathological parameters were compared between both cohorts. Logistic regression models were used to identify independent predictors of iPCa.
Demographic parameters were similar between both cohorts. The median PSA levels were 14.2 ng/ml (11.5–19.9) and 4 ng/ml (2.4–6.0). The prostate volume was significantly higher in the high PSA group (105 cc vs. 75 cc; p < 0.001). Correspondingly, the PSA density was significantly increased in the high PSA cohort compared to the low PSA cohort (0.14 vs. 0.05; p < 0.001). The overall detection rate of iPCa showed no difference between groups (9.5% vs. 9.9%). More preoperative prostate biopsies were performed in the high PSA group compared to the low PSA group (46.8% vs. 17.6%; p < 0.001). However, the rate of false negative results was comparable between groups (12.7% vs. 11.1%; p = 0.726). In logistic regression models all PSA-related parameters failed to predict iPCa.
PSA-guided approaches to predict iPCa in LUTS patients with very large prostates are not accurate. This finding is useful in clinical practice for counselling our patients and to prevent unwarranted diagnostic procedures.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. NEngl J Med 317(15):909–916
Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151(5):1283–1290
Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA et al (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117(6):1210–1219
Bohnen AM, Groeneveld FP, Bosch JL (2007) Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 51(6):1645–1652 (discussion 52-3)
Kayikci A, Cam K, Kacagan C, Tekin A, Ankarali H (2012) Free prostate-specific antigen is a better tool than total prostate-specific antigen at predicting prostate volume in patients with lower urinary tract symptoms. Urology 80(5):1088–1092
Morote J, Encabo G, Lopez M, de Torres IM (2000) Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 38(1):91–95
Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH et al (2000) Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 163(1):13–20
Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T et al (1999) Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group Urol 54(4):662–669
Djavan B, Fong YK, Harik M, Milani S, Reissigl A, Chaudry A et al (2004) Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 64(6):1144–1148
Patel DN, Feng T, Simon RM, Howard LE, Vidal AC, Moreira DM et al (2018) PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer Prostatic Dis 21(2):238–244
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEngl J Med 349(25):2387–2398
Roehrborn CG (2006) Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 97(4):734–741
Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099–1109
Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A et al (2017) “Finding the needle in a haystack: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol 35(11):1777–1782
Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C (2018) HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol 36(12):2035–2041
Kang MY, Ku JH, Oh SJ (2010) Non-invasive parameters predicting bladder outlet obstruction in Korean men with lower urinary tract symptoms. J Korean Med Sci 25(2):272–275
Huang Y, Li ZZ, Huang YL, Song HJ, Wang YJ (2018) Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: a meta-analysis. Medicine (Baltimore) 97(13):e0249
Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE (2015) Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue. J Endourol 29(1):41–46
Kim M, Song SH, Ku JH, Oh SJ, Paick JS (2014) Prostate cancer detected after Holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography. Int Urol Nephrol 46(11):2079–2085
Naspro R, Freschi M, Salonia A, Guazzoni G, Girolamo V, Colombo R et al (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171(3):1203–1206
Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR (2011) Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol 18(7):543–547
Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M (2005) Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol 39(4):289–293
Jones JS, Follis HW, Johnson JR (2009) Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis 12(1):57–60
Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B et al (2014) Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol 2014:627290
Rivera ME, Frank I, Viers BR, Rangel LJ, Krambeck AE (2014) Holmium laser enucleation of the prostate and perioperative diagnosis of prostate cancer: an outcomes analysis. J Endourol 28(6):699–703
Sakamoto H, Matsumoto K, Hayakawa N, Maeda T, Sato A, Ninomiya A et al (2014) Preoperative parameters to predict incidental (T1a and T1b) prostate cancer. Can Urol Assoc J 8(11–12):E815–E820
Voigt S, Huttig F, Koch R, Propping S, Propping C, Grimm MO et al (2011) Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia? Prostate 71(12):1325–1331
Elkoushy MA, Elshal AM, Elhilali MM (2015) Incidental prostate cancer diagnosis during holmium laser enucleation: assessment of predictors, survival, and disease progression. Urology 86(3):552–557
Misrai V, Pasquie M, Bordier B, Guillotreau J, Gryn A, Palasse J et al. (2020) Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma. World J Urol 38(4):993–1000. https://doi.org/10.1007/s00345-019-02823-6
Lee H, Hwang SI, Lee HJ, Byun SS, Lee SE, Hong SK (2018) Diagnostic performance of diffusion-weighted imaging for prostate cancer: peripheral zone versus transition zone. PLoS ONE 13(6):e0199636
Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA (1996) Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. Prostate Cancer Edu Council Urol 47(6):863–869
Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M et al (2005) The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer 104(5):993–1003
Filella X, Foj L (2018) Novel biomarkers for prostate cancer detection and prognosis. Adv Exp Med Biol 1095:15–39
Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3):963–968
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal participant rights statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Magistro, G., Keller, P., Westhofen, T. et al. The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates. World J Urol (2020). https://doi.org/10.1007/s00345-020-03321-w
- Benign prostatic hyperplasia
- Lower urinary tract symptoms
- Holmium laser enucleation of the prostate (HoLEP)
- Incidental prostate cancer